Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Vertex Pharmaceuticals
  6. Summary
    VRTX   US92532F1003

VERTEX PHARMACEUTICALS

(VRTX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/10/2022 01/11/2022 01/12/2022 01/13/2022 01/14/2022 Date
223.96(c) 226.15(c) 226.14(c) 226.58(c) 234.06(c) Last
1 844 602 1 459 038 1 225 022 1 750 471 2 178 366 Volume
+0.95% +0.98% -0.00% +0.19% +3.30% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 7 501 M - -
Net income 2021 2 296 M - -
Net cash position 2021 8 318 M - -
P/E ratio 2021 26,6x
Yield 2021 -
Sales 2022 8 231 M - -
Net income 2022 3 007 M - -
Net cash position 2022 12 053 M - -
P/E ratio 2022 20,3x
Yield 2022 -
Capitalization 59 510 M 59 510 M -
EV / Sales 2021 6,82x
EV / Sales 2022 5,77x
Nbr of Employees 3 400
Free-Float -
More Financials
Company
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales break down by type of income as follows: - income from sales of products (99.9%); - royalties and income from partnership, research, and development agreements (0.1%). Net sales break down geographically... 
Read more
More about the company
Ratings of Vertex Pharmaceuticals
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about VERTEX PHARMACEUTICALS
01/12Vertex Pharmaceuticals - European Commission Approves KAFTRIO (ivacaftor/tezacaftor/ele..
AQ
01/11Vertex's Cystic Fibrosis Combo Gets Extended EU Nod For Treating Children
MT
01/11Vertex Secures European Commission's Approval for Kaftrio With Ivacaftor as Treatment f..
MT
01/11European Commission Approves KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination..
BU
01/11Vertex Pharmaceuticals Incorporated announces European Commission Approves KAFTRIO® (iv..
CI
01/06RBC Raises Price Target on Vertex Pharmaceuticals to $268 From $265, Maintains Outperfo..
MT
01/04Vertex to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 10
BU
2021Diversified Healthcare Trust's Sale of 35% Stake in Boston Properties Lifts Liquidity A..
MT
2021Diversified Healthcare Trust to Sell 35% Stake in Joint Venture for $378 Million
MT
2021Wells Fargo Reinstates Vertex Pharmaceuticals With Overweight Rating, $270 Price Target
MT
2021PUMP / DUMP #13 : This week's gainers and losers
2021RBC Lifts Price Target on Vertex Pharmaceuticals to $265 From $250, Citing 'Strong' Pro..
MT
2021Equities Led Higher Midday by Energy, Financials Following BioNTech CEO Comment on Vacc..
MT
2021MIDDAY REPORT : US Stocks Led Higher by Energy, Financials Following BionTech CEO Comment ..
MT
2021Vertex Pharmaceuticals Up Over 7%, Best Performer in The S&P 500 and Nasdaq 100 So Far ..
DJ
More news
News in other languages on VERTEX PHARMACEUTICALS
01/11Vertex obtient l'approbation de la Commission européenne pour Kaftrio et l'Ivacaftor co..
01/11Vertex Pharmaceuticals Incorporated annonce que la Commission européenne approuve KAFTR..
2021Selon B. Riley, la vente par Diversified Healthcare Trust de 35 % de sa participation d..
2021NOVARTIS-CHEF : Möglicher Verkauf von Sandoz stösst auf Interesse
2021PUMP / DUMP #40 : Les Tops & Flops de la semaine
More news
Analyst Recommendations on VERTEX PHARMACEUTICALS
More recommendations
Analysis
PUMP / DUMP #13 : This week's gainers and losers
Chart VERTEX PHARMACEUTICALS
Duration : Period :
Vertex Pharmaceuticals Technical Analysis Chart | VRTX | US92532F1003 | MarketScreener
Technical analysis trends VERTEX PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 234,06 $
Average target price 263,74 $
Spread / Average Target 12,7%
EPS Revisions
Managers and Directors
Reshma Kewalramani President, Chief Executive Officer & Director
Charles F. Wagner Chief Financial Officer & Executive Vice President
Jeffrey M. Leiden Executive Chairman
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Carmen Bozic Chief Medical Officer & EVP-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
VERTEX PHARMACEUTICALS6.58%59 510
GILEAD SCIENCES, INC.-1.16%90 027
REGENERON PHARMACEUTICALS, INC.-2.58%64 327
WUXI APPTEC CO., LTD.-3.88%52 722
BIONTECH SE-23.97%47 338
BEIGENE, LTD.-11.92%24 519